Guardion Subsidiary VectorVision Receives Approval from Korean Intellectual Property Office for CSV-2000 Trademark
July 15 2020 - 9:00AM
VectorVision®, a wholly-owned subsidiary of Guardion Health
Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a
specialty health sciences company that develops medical foods and
medical devices in the ocular health marketplace and which is
developing nutraceuticals it believes will provide medicinal and
health benefits to consumers, announced that it has received
approval from the Korean Intellectual Property Office in accordance
with the Korean Trademark Act to trademark the CSV-2000. The Korean
Intellectual Property Office is the national patent and
intellectual property office of South Korea. VectorVision’s
CSV-2000 is the first and only computer vision testing device that
provides for standardized contrast sensitivity testing, along with
the full range of visual acuity, color, astigmatism, fixation and
other vision tests.
The VectorVision CSV-2000 is also the only
device that contains the AcQviz patented technology for
automatically calibrating the monitor light source. AcQviz
continuously measures the monitor light level and adjusts the level
to 85 cd/m2 – the light level recommended for vision testing by the
U.S. National Academy of Science Working Group on Vision Standards,
the U.S. Food and Drug Administration and the American National
Standards Institute. The AcQviz device is housed in the upper
left-hand corner of the screen and communicates via specialized
software and miniaturized hardware with the luminance control of
the monitor. By incorporating the AcQviz standardization technology
with the VectorVision contrast sensitivity test, the CSV-2000
brings true next generation technology to ophthalmic
examinations.
“We are pleased to announce that we have
received approval from the Korean Intellectual Property Office for
the VectorVision CSV-2000, the first and only device that provides
standardized contrast sensitivity testing along with the full range
of visual acuity, color, astigmatism, fixation and other standard
vision tests,” said Dr. David Evans, Ph.D., Guardion’s Interim
President and Chief Executive Officer, as well as the founder of
VectorVision prior to its acquisition by Guardion in 2017. “This
approval is another milestone for Guardion as we continue our
efforts to establish meaningful legal protection for our
proprietary products and technologies, while we are also continuing
to focus on increasing market share, both domestically and
internationally.”
About Guardion Health Sciences, Inc.
Guardion is a specialty health sciences company
(i) that develops medical foods and medical devices in the ocular
health marketplace and (ii) that is developing nutraceuticals that
the Company believes will provide medicinal and health benefits to
consumers. Information and risk factors with respect to Guardion
and its business, including its ability to successfully develop and
commercialize its proprietary products and technologies, may be
obtained in the Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision’s®
patented technology is considered the standard of care for clinical
trials. VectorVision® is a wholly owned subsidiary of Guardion.
About NutriGuard™
NutriGuard™ formulates high-quality
nutraceuticals which are designed to supplement consumers’ diets.
NutriGuard uses industry standards to establish the safety and
efficacy of the products it develops and markets, maintains that
commitment through prudent manufacturing and quality assurance
programs, and only uses manufacturers who comply with FDA current
Good Manufacturing Practices (cGMP) requirements. Guardion plans to
increase NutriGuard’s existing customer base and build on its
product platform by making NutriGuard products available to
patients directly and through recommendations by their
physicians.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
impact of the COVID-19 pandemic on the Company’s business,
operations and the economy in general, and the Company’s ability to
successfully develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward- looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Michael PorterTelephone: (212) 564-4700 E-mail:
mike@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024